Variable Correlations Seen Between Geographic Atrophy Enlargement Rates in Fellow Eyes
Medically reviewed by Drugs.com
via HealthDayTUESDAY, April 7, 2026 -- The geographic atrophy (GA) enlargement rate in one eye does not consistently predict the enlargement rate in the fellow eye, according to a study published online April 2 in JAMA Ophthalmology.
Leon von der Emde, M.D., from the National Institutes of Health in Bethesda, Maryland, and colleagues quantified the correlation of GA enlargement rates between fellow eyes. A post hoc analysis of the Age-Related Eye Disease Study 2 included 386 eyes of 193 participants.
The researchers found that correlations in enlargement rates varied substantially by transformation used as follows: moderate for untransformed (r = 0.51; 95 percent confidence interval [CI], 0.41 to 0.61), weak-to-moderate for square root-transformed (r = 0.38; 95 percent CI, 0.25 to 0.49), and very weak for perimeter-adjusted (r = 0.11; 95 percent CI, −0.03 to 0.25) rates. In large GA, the correlation was consistently weaker than small GA: 0.30 versus 0.63 for untransformed, 0.38 versus 0.46 for square root, and 0.03 versus 0.22 for perimeter. Correlation was strongest for extrafoveal GA, intermediate for subfoveal GA, and weakest for discordant pairs for GA location using untransformed rates, with a similar pattern for square root rates. Correlation was similar for unifocal, multifocal, and discordant pairs for focality using untransformed rates.
"These data challenge the validity of using GA in the fellow eye as an internal control for disease progression in clinical trial design," Kelly Donovan, M.D., Ph.D., from Duke University in Durham, North Carolina, writes in an accompanying editorial.
One author disclosed ties to the pharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2026-04-08 01:59
Read more
- Genentech Announces Positive Phase II Results for Petrelintide, an Amylin Analog Developed for People Living With Overweight and Obesity
- Laser Red-Light Therapy Delivers Irradiance Levels Exceeding Safety Limits
- Novo Nordisk Expands U.S. Patient Access to FDA-Approved Semaglutide Medicines Through Hims & Hers in Response to a Shift in Their U.S. GLP-1 Business Model
- Younger Stroke Survivors Have More Difficulty Concentrating
- Global Maternal Mortality Ratio Reported at 190.5 Deaths/100,000 Livebirths in 2023
- U.S. FDA Approves Bristol Myers Squibb’s Sotyktu (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions